The low-lying electronic states of Be(2)H(2) have been investigated using an ab initio methodology in order to explore the nature of the Be-Be bonding in this tetra-atomic molecule. The donation of two electrons from the antibonding molecular orbital mainly associated with Be(2) to orbitals mainly associated with the 1s of the H atoms is found to be responsible for the strong Be-Be bond in this tetra-atomic molecule compared with the Be(2) diatomic. In addition to the linear form, a cyclic isomer of Be(2)H(2) has been identified at about 1.47 eV above the linear structure. This structure results from an avoided crossing taking place above the lowest dissociation limit giving two BeH fragments. For the linear structure, a six dimensional potential energy surface has been generated and the rovibrational levels have been computed variationally. The fundamental modes obtained are found to be in well agreement with those detected experimentally. For Be(2)H(2) (Be(2)D(2)), the antisymmetric stretching mode ν(3) is computed at 2028.6 (1519.3) cm(-1).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jp307531f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lateralization of the Aberrant Amplitude of Low-Frequency Fluctuation within the Default Mode Network in Patients with Mild Cognitive Impairment.
Acad Radiol
January 2025
Department of Radiology, Eye & ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China (Q.X.). Electronic address:
Rationale And Objectives: Alzheimer's disease (AD) is the most common pathogenesis of dementia, and mild cognitive impairment (MCI) is considered as the intermediate stage from normal elderly to AD. Early detection of MCI is an essential step for the timely intervention of AD to slow the progression of this disease. Different form previous studies in the whole-brain spontaneous activities, this research aimed to explore the low-frequency amplitude spectrum activities of patients with MCI within the default mode network (DMN), which has been involved in the process of maintaining normal cognitive function.
View Article and Find Full Text PDFSurgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
Clin Lung Cancer
December 2024
Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, Liverpool, UK.
Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.
Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.
Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.
Clin Lung Cancer
December 2024
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Objective: To determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC).
Materials And Methods: SEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first.
Voice Quality as Digital Biomarker in Bipolar Disorder: A Systematic Review.
J Voice
January 2025
Department of Surgery, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium; Division of Laryngology and Bronchoesophagology, Department of Otolaryngology Head Neck Surgery, EpiCURA Hospital, Baudour, Belgium; Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France; Department of Otolaryngology, Elsan Hospital, Paris, France. Electronic address:
Background: Voice analysis has emerged as a potential biomarker for mood state detection and monitoring in bipolar disorder (BD). The systematic review aimed to summarize the evidence for voice analysis applications in BD, examining (1) the predictive validity of voice quality outcomes for mood state detection, and (2) the correlation between voice parameters and clinical symptom scales.
Methods: A PubMed, Scopus, and Cochrane Library search was carried out by two investigators for publications investigating voice quality in BD according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.
Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.
Clin Lymphoma Myeloma Leuk
December 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Hematology Center, Peking University People's Hospital, Qingdao, China. Electronic address:
Aim: To describe tyrosine kinase inhibitor (TKI) treatment patterns and analyze co-variates of TKI switch for chronic myeloid leukemia (CML) patients in a center from China.
Methods: A retrospectively study was designed to analyze TKI switching patterns, reasons and associated covariates in patients with CP-CML.
Results: 1766 patients receiving initial imatinib (n = 1374), nilotinib (n = 254), dasatinib (n = 63) and flumatinib (n = 75) therapy were retrospectively interrogated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!